Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism

摘要

Background Sclerostin is an osteocyte-secreted soluble antagonist of the Wnt/-catenin signaling pathway requisite for osteoblast development and activity. The regulation of sclerostin expression in bone is complex. Parathyroid hormone (PTH) is recognized to be an important suppressor. Circulating sclerostin levels are 2- to 4-fold higher in patients with end-stage renal disease as compared with individuals with normal renal function.